List of Toviaz drug patents
Toviaz is owned by Pfizer.
Toviaz contains Fesoterodine Fumarate.
Toviaz has a total of 8 drug patents out of which 2 drug patents have expired.
Expired drug patents of Toviaz are:
- US6858650*PED
- US6858650
Toviaz was authorised for market use on 31 October, 2008.
Toviaz is available in tablet, extended release;oral dosage forms.
Toviaz can be used as treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
The generics of Toviaz are possible to be released after 07 December, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(6 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6858650
(Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(25 days ago) | |
| US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
| US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
| US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
|
US7807715
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
|
US8088398
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
|
US8501723
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Jun 17, 2024 |
| Pediatric Exclusivity (PED) | Dec 17, 2024 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic